What is Modified GRF 1-29?
Modified GRF 1-29 is a label used for modified growth-hormone-releasing-factor fragments, often described by sellers as “CJC no DAC.” The selected primary study concerns albumin-binding conjugates rather than a confirmed DAC-free preparation.
Biological role or research focus
GRF analogue identity and hormone signaling.
These are related-conjugate findings. They do not establish the half-life, effectiveness, or safety of a product labeled Modified GRF 1-29 without DAC.
Names you may encounter
Mod GRF 1-29 · CJC-1295 no DAC · CJC no DAC
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Modified GRF fragment label; DAC-free preparation requires confirmation
- Research focus
- GRF analogue identity and hormone signaling
- Featured evidence
- Related conjugate · Animal and cell study
- Source check
- October 4, 2026
Quick answers
- Is Modified GRF 1-29 FDA approved?
- No. No FDA-approved drug contains Modified GRF 1-29. Source ↗
- Is Modified GRF 1-29 safe?
- Unapproved growth-hormone-releasing peptide with no published human safety studies of this exact product; effects of long-term hormone stimulation are unknown. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Modified GRF 1-29 banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S2.2.4 Growth hormone releasing factors). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Albumin-binding GRF conjugates and CJC-1295 (2005) | Cultured rat anterior-pituitary cells and male rats. |
Claim check
Partly supported Are CJC-1295 and ipamorelin a safe, natural way to boost growth hormone?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Related conjugate · Animal and cell study · 2005
Albumin-binding GRF conjugates and CJC-1295
What did this publication test, and what did it find?
- Population / model
- Cultured rat anterior-pituitary cells and male rats.
- Study design
- Synthesis and testing of maleimido GRF derivatives, albumin conjugation, hormone-release assays, and rat pharmacokinetic measurements.
- Main finding
- The conjugates remained active in hormone-release experiments. The selected CJC-1295 conjugate showed extended circulating exposure and albumin association.
- Limits & context
- These are related-conjugate findings. They do not establish the half-life, effectiveness, or safety of a product labeled Modified GRF 1-29 without DAC.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming Modified GRF 1-29 as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 1 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Glycine-modified growth hormone secretagogues identified in seized doping material. ↗
Drug testing and analysis · 2019 Feb · Journal Article
Risks & interactions
Unapproved growth-hormone-releasing peptide with no published human safety studies of this exact product; effects of long-term hormone stimulation are unknown.
No published human safety studies of Modified GRF 1-29 were found. Related GRF-conjugate data come from rat and cell experiments, which cannot show safety in people or the effects of repeated growth-hormone stimulation.
Unassessed: no human safety data
It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: hGRF(1-29)-albumin bioconjugates and CJC-1295 in rats (2005) ↗
Safety & what remains unknown
A hormone-release response is not proof of clinical benefit or safe long-term endocrine stimulation.
Evidence boundaries
These are related-conjugate findings. They do not establish the half-life, effectiveness, or safety of a product labeled Modified GRF 1-29 without DAC.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S2.2.4 Growth hormone releasing factors
Not named under this name, but S2.2.4 prohibits GHRH and its analogues (e.g., CJC-1295, sermorelin); likely covered. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
This page makes the distinction between modified fragments, unmodified sermorelin, and DAC-containing CJC-1295 explicit. A catalog nickname is not a complete sequence definition.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Biology & proposed mechanism
The paper tested GRF-receptor activity and engineered albumin binding to extend exposure. Removing the albumin-binding component changes the intervention and invalidates direct transfer of its pharmacokinetics.
Questions worth asking
- Can CJC-1295 with DAC half-life findings be assigned to “no DAC”?
- What material, population, and route were actually studied?
- These are related-conjugate findings. They do not establish the half-life, effectiveness, or safety of a product labeled Modified GRF 1-29 without DAC.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Can CJC-1295 with DAC half-life findings be assigned to “no DAC”?
No. The albumin-binding modification is central to the cited paper’s prolonged exposure. The DAC-free product requires its own identity and evidence.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
